HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumers staying true to organics

This article was originally published in The Rose Sheet

Executive Summary

Consumers are not abandoning the organic lifestyle in the depressed economy, according to a new study from market researcher Mintel. According to the firm, nearly 40% of consumers say they have not changed their organic purchasing habits, and only 3% have stopped buying organic altogether. Some heavy users of natural and organic products have traded down to cheaper options, Mintel senior analyst David Browne notes, but "less frequent consumers of organic products have shown that they haven't shifted their behavior. This is good news," he says, because the group may begin buying more organic items once the economy is up and running (see 1Mintel Watching For Mood-Enhancing Beauty, Nature/Science Fusions In 2010 ).

You may also be interested in...



Mintel Watching For Mood-Enhancing Beauty, Nature/Science Fusions In 2010

Impacted by the economic recession, consumers are looking for personal-care products that offer protection and maybe even lift their spirits, Mintel suggests in its predictions for 2010

Normality Reasserts Itself For Biotech IPOs

The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.

Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements

Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel